Literature DB >> 23733688

Erythropoietin.

Roland H Wenger1, Armin Kurtz.   

Abstract

The hormone erythropoietin (Epo) is the main humoral regulator of erythropoiesis. It binds to specific receptors belonging to the cytokine receptor superfamily. Epo stimulates proliferation and differentiation of erythroid precursor cells, but may also bind to and exert some additional effects in nonhemopoietic tissues. It is mainly produced in the kidneys and to minor extents also in the liver and in the brain. The plasma concentration of erthyropoietin is inversely related to the oxygen content of the blood. The secretion of Epo into the circulation and hence its plasma concentrations are mainly determined by the transcription rate of the Epo gene, which itself is essentially under control of the cellular oxygen concentration. Sinks of the oxygen concentrations increase the activity of the hypoxia-inducible transcription factor (HIF), which in turn triggers Epo gene transcription. Disorders of kidney function lead to inappropriate Epo production, what may result in anemia or polycythemia. 2011 American Physiological Society

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 23733688     DOI: 10.1002/cphy.c100075

Source DB:  PubMed          Journal:  Compr Physiol        ISSN: 2040-4603            Impact factor:   9.090


  16 in total

1.  Brain structure and perfusion in relation to serum renal function indexes in healthy young adults.

Authors:  Siyu Liu; Chunli Wang; Ying Yang; Huanhuan Cai; Min Zhang; Li Si; Shujun Zhang; Yuanhong Xu; Jiajia Zhu; Yongqiang Yu
Journal:  Brain Imaging Behav       Date:  2021-10-28       Impact factor: 3.978

Review 2.  Erythropoietin.

Authors:  H Franklin Bunn
Journal:  Cold Spring Harb Perspect Med       Date:  2013-03-01       Impact factor: 6.915

3.  Selected hematological, biochemical, and acid-base variables of Paso Fino horses living at different altitudes.

Authors:  Camilo Jaramillo; María P Arias; Diana Mosqueda; Shannon Darby; David Renaud; Diego E Gómez
Journal:  Trop Anim Health Prod       Date:  2020-11-17       Impact factor: 1.559

4.  Combination of erythropoietin and sildenafil can effectively attenuate hypoxia-induced pulmonary hypertension in mice.

Authors:  Victor Samillan; Thomas Haider; Johannes Vogel; Caroline Leuenberger; Matthias Brock; Colin Schwarzwald; Max Gassmann; Louise Ostergaard
Journal:  Pulm Circ       Date:  2013-12       Impact factor: 3.017

Review 5.  Now a Nobel gas: oxygen.

Authors:  Joachim Fandrey; Johannes Schödel; Kai-Uwe Eckardt; Dörthe M Katschinski; Roland H Wenger
Journal:  Pflugers Arch       Date:  2019-11-22       Impact factor: 3.657

Review 6.  Neocytolysis: How to Get Rid of the Extra Erythrocytes Formed by Stress Erythropoiesis Upon Descent From High Altitude.

Authors:  Heimo Mairbäurl
Journal:  Front Physiol       Date:  2018-04-05       Impact factor: 4.566

7.  Preoperative blood morphology and incidence of acute kidney injury after on-pump coronary artery bypass grafting - a single-center preliminary report.

Authors:  Bartłomiej Perek; Dawid Maison; Szymon Budnick; Kinga Gębala; Veronica Casadei; Daniela Dadej; Artur Chmielewski; Marcin Ligowski; Piotr Buczkowski; Anna Perek; Marek Jemielity
Journal:  Kardiochir Torakochirurgia Pol       Date:  2018-03-28

8.  Age-dependent impairment of the erythropoietin response to reduced central venous pressure in HFpEF patients.

Authors:  David Montero; Thomas Haider; Jens Barthelmes; Jens P Goetze; Silviya Cantatore; Carsten Lundby; Isabella Sudano; Frank Ruschitzka; Andreas J Flammer
Journal:  Physiol Rep       Date:  2019-03

Review 9.  Extreme Terrestrial Environments: Life in Thermal Stress and Hypoxia. A Narrative Review.

Authors:  Martin Burtscher; Hannes Gatterer; Johannes Burtscher; Heimo Mairbäurl
Journal:  Front Physiol       Date:  2018-05-16       Impact factor: 4.566

Review 10.  Valid Presumption of Shiga Toxin-Mediated Damage of Developing Erythrocytes in EHEC-Associated Hemolytic Uremic Syndrome.

Authors:  Johanna Detzner; Gottfried Pohlentz; Johannes Müthing
Journal:  Toxins (Basel)       Date:  2020-06-04       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.